Tag Archive for: Destiny Pharma

Destiny Pharma plc – US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections

/in

Brighton, United Kingdom – 25 January 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, notes an increased focus on the importance of infection prevention by the Center for Disease Control (“CDC”), Food and Drug Administration (“FDA”), and the medical community in […]

Read more

Destiny Pharma plc – XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID

/in

Brighton, United Kingdom, 15th November 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. Read more…

Read more

Destiny Pharma announces start of a new XF-73 research programme

/in

Destiny Pharma announces start of a new XF-73 research programme Aim to test XF-73 as a potential preventive medicine for Oral Mucositis Oral Mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2m cancer patients every year Brighton, United Kingdom – 05 July 2022 – Destiny Pharma plc (AIM: DEST), […]

Read more

Destiny Pharma: Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme

/in

Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme Phase 3 can use similar primary endpoint to the very successful Phase 2b clinical study New European report underpins clinical need and market opportunity of XF-73 Nasal Brighton, United Kingdom, 8 February 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]

Read more

Destiny Pharma Lancet Report

/in

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Important Lancet report highlights growing threat of Antimicrobial Resistance with over one million deaths per year Destiny Pharma’s XF platform is delivering effective drug candidates that also address the threat of AMR Brighton, United Kingdom, 21 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative […]

Read more